Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Transcriptomic analysis of genetically defined autism candidate genes reveals common mechanisms of action.

Lanz TA, Guilmette E, Gosink MM, Fischer JE, Fitzgerald LW, Stephenson DT, Pletcher MT.

Mol Autism. 2013 Nov 15;4(1):45. doi: 10.1186/2040-2392-4-45.

2.

10 Catholic hospitals on Best Places to Work List.

Underwood M, O'Connor J, Harrison CH, Fitzgerald LW, Karam C, Cron BF, Demulling D, Sterbach M, Sister Catherine Kelly, Bowman J.

Health Prog. 2011 Jul-Aug;92(4):61-9. No abstract available.

PMID:
21838116
3.

6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics.

Favor DA, Powers JJ, White AD, Fitzgerald LW, Groppi V, Serpa KA.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5666-9. doi: 10.1016/j.bmcl.2010.08.023. Epub 2010 Aug 8.

PMID:
20801650
4.

Pharmacological characterization of mitogen-activated protein kinase activation by recombinant human 5-HT2C, 5-HT2A, and 5-HT2B receptors.

Knauer CS, Campbell JE, Chio CL, Fitzgerald LW.

Naunyn Schmiedebergs Arch Pharmacol. 2009 May;379(5):461-71. doi: 10.1007/s00210-008-0378-4. Epub 2008 Dec 5.

PMID:
19057895
5.

Heteroatom-linked indanylpyrazines are corticotropin releasing factor type-1 receptor antagonists.

Corbett JW, Rauckhorst MR, Qian F, Hoffman RL, Knauer CS, Fitzgerald LW.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6250-6. Epub 2007 Sep 7.

PMID:
17888659
6.

2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists.

Ennis MD, Hoffman RL, Ghazal NB, Olson RM, Knauer CS, Chio CL, Hyslop DK, Campbell JE, Fitzgerald LW, Nichols NF, Svensson KA, McCall RB, Haber CL, Kagey ML, Dinh DM.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2369-72.

PMID:
12824036
7.

Novel, highly potent, selective 5-HT2A/D2 receptor antagonists as potential atypical antipsychotics.

Lee T, Robichaud AJ, Boyle KE, Lu Y, Robertson DW, Miller KJ, Fitzgerald LW, McElroy JF, Largent BL.

Bioorg Med Chem Lett. 2003 Feb 24;13(4):767-70.

PMID:
12639577
8.

CRF ligands via Suzuki and Negishi couplings of 3-pyridyl boronic acids or halides with 2-benzyloxy-4-chloro-3-nitropyridine.

Arvanitis AG, Arnold CR, Fitzgerald LW, Frietze WE, Olson RE, Gilligan PJ, Robertson DW.

Bioorg Med Chem Lett. 2003 Jan 20;13(2):289-91.

PMID:
12482442
9.

Imidazo[4,5-c]pyridines as corticotropin releasing factor receptor ligands.

Arvanitis AG, Rescinito JT, Arnold CR, Wilde RG, Fitzgerald LW, Zaczek R, Hartig PR, Grossman S, Arneric SP, Gilligan PJ, Olson RE, Robertson DW.

Bioorg Med Chem Lett. 2003 Jan 6;13(1):129-31.

PMID:
12467632
10.

Imidazo[4,5-b]pyridines as corticotropin releasing factor receptor ligands.

Arvanitis AG, Rescinito JT, Arnold CR, Wilde RG, Cain GA, Sun JH, Yan JS, Teleha CA, Fitzgerald LW, McElroy J, Zaczek R, Hartig PR, Grossman S, Arneric SP, Gilligan PJ, Olson RE, Robertson DW.

Bioorg Med Chem Lett. 2003 Jan 6;13(1):125-8.

PMID:
12467631
11.

Synthesis and evaluation of imidazo[1,5-a]pyrazines as corticotropin releasing hormone receptor ligands.

Hartz RA, Gilligan PJ, Nanda KK, Tebben AJ, Fitzgerald LW, Miller K.

Bioorg Med Chem Lett. 2002 Feb 11;12(3):291-4.

PMID:
11814780
12.

The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist.

Gilligan PJ, Baldauf C, Cocuzza A, Chidester D, Zaczek R, Fitzgerald LW, McElroy J, Smith MA, Shen HS, Saye JA, Christ D, Trainor G, Robertson DW, Hartig P.

Bioorg Med Chem. 2000 Jan;8(1):181-9.

PMID:
10968277
13.

4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.

He L, Gilligan PJ, Zaczek R, Fitzgerald LW, McElroy J, Shen HS, Saye JA, Kalin NH, Shelton S, Christ D, Trainor G, Hartig P.

J Med Chem. 2000 Feb 10;43(3):449-56.

PMID:
10669572
14.

Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.

Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW.

Mol Pharmacol. 2000 Jan;57(1):75-81.

PMID:
10617681
15.

Messenger RNA editing of the human serotonin 5-HT2C receptor.

Fitzgerald LW, Iyer G, Conklin DS, Krause CM, Marshall A, Patterson JP, Tran DP, Jonak GJ, Hartig PR.

Neuropsychopharmacology. 1999 Aug;21(2 Suppl):82S-90S.

16.

Thiazolo[4,5-d]pyrimidine thiones and -ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists.

Beck JP, Curry MA, Chorvat RJ, Fitzgerald LW, Gilligan PJ, Zaczek R, Trainor GL.

Bioorg Med Chem Lett. 1999 Apr 19;9(8):1185-8.

PMID:
10328310
17.

Purin-8-ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists.

Beck JP, Arvanitis AG, Curry MA, Rescinito JT, Fitzgerald LW, Gilligan PJ, Zaczek R, Trainor GL.

Bioorg Med Chem Lett. 1999 Apr 5;9(7):967-72.

PMID:
10230622
18.

High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.

Fitzgerald LW, Conklin DS, Krause CM, Marshall AP, Patterson JP, Tran DP, Iyer G, Kostich WA, Largent BL, Hartig PR.

J Neurochem. 1999 May;72(5):2127-34.

19.

Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.

Chorvat RJ, Bakthavatchalam R, Beck JP, Gilligan PJ, Wilde RG, Cocuzza AJ, Hobbs FW, Cheeseman RS, Curry M, Rescinito JP, Krenitsky P, Chidester D, Yarem JA, Klaczkiewicz JD, Hodge CN, Aldrich PE, Wasserman ZR, Fernandez CH, Zaczek R, Fitzgerald LW, Huang SM, Shen HL, Wong YN, Chien BM, Arvanitis A, et al.

J Med Chem. 1999 Mar 11;42(5):833-48.

PMID:
10072681
20.

Pharmacological and biochemical characterization of a recombinant human galanin GALR1 receptor: agonist character of chimeric galanin peptides.

Fitzgerald LW, Patterson JP, Conklin DS, Horlick R, Largent BL.

J Pharmacol Exp Ther. 1998 Nov;287(2):448-56.

PMID:
9808667
21.

Characterization of [125I]sauvagine binding to CRH2 receptors: membrane homogenate and autoradiographic studies.

Rominger DH, Rominger CM, Fitzgerald LW, Grzanna R, Largent BL, Zaczek R.

J Pharmacol Exp Ther. 1998 Jul;286(1):459-68.

PMID:
9655891
22.

Chronic ethanol administration regulates the expression of GABAA receptor alpha 1 and alpha 5 subunits in the ventral tegmental area and hippocampus.

Charlton ME, Sweetnam PM, Fitzgerald LW, Terwilliger RZ, Nestler EJ, Duman RS.

J Neurochem. 1997 Jan;68(1):121-7.

23.

Biochemical adaptations in the mesolimbic dopamine system in response to repeated stress.

Ortiz J, Fitzgerald LW, Lane S, Terwilliger R, Nestler EJ.

Neuropsychopharmacology. 1996 Jun;14(6):443-52.

25.

Biochemical actions of chronic ethanol exposure in the mesolimbic dopamine system.

Ortiz J, Fitzgerald LW, Charlton M, Lane S, Trevisan L, Guitart X, Shoemaker W, Duman RS, Nestler EJ.

Synapse. 1995 Dec;21(4):289-98.

PMID:
8869159
26.

Regulation of neuronal nitric oxide synthase by chronic ethanol ingestion.

Fitzgerald LW, Charlton ME, Duman RS, Nestler EJ.

Synapse. 1995 Sep;21(1):93-5. No abstract available.

PMID:
8525467
27.

Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs.

Fitzgerald LW, Deutch AY, Gasic G, Heinemann SF, Nestler EJ.

J Neurosci. 1995 Mar;15(3 Pt 2):2453-61.

28.

Molecular and cellular adaptations in signal transduction pathways following ethanol exposure.

Fitzgerald LW, Nestler EJ.

Clin Neurosci. 1995;3(3):165-73. Review.

PMID:
8612061
29.

Chronic ingestion of ethanol up-regulates NMDAR1 receptor subunit immunoreactivity in rat hippocampus.

Trevisan L, Fitzgerald LW, Brose N, Gasic GP, Heinemann SF, Duman RS, Nestler EJ.

J Neurochem. 1994 Apr;62(4):1635-8.

PMID:
8133290
30.

Lateralized changes in prefrontal cortical dopamine activity induced by controllable and uncontrollable stress in the rat.

Carlson JN, Fitzgerald LW, Keller RW Jr, Glick SD.

Brain Res. 1993 Dec 10;630(1-2):178-87.

PMID:
8118684
31.
32.

Specificity of behavioral and neurochemical dysfunction in the chakragati mouse: a novel genetic model of a movement disorder.

Fitzgerald LW, Ratty AK, Teitler M, Gross KW, Glick SD.

Brain Res. 1993 Apr 16;608(2):247-58.

PMID:
8495359
33.

Asymmetric elevation of striatal dopamine D2 receptors in the chakragati mouse: neurobehavioral dysfunction in a transgenic insertional mutant.

Fitzgerald LW, Miller KJ, Ratty AK, Glick SD, Teitler M, Gross KW.

Brain Res. 1992 May 15;580(1-2):18-26.

PMID:
1354555
34.

Ontogeny of hyperactivity and circling behavior in a transgenic insertional mutant mouse.

Fitzgerald LW, Ratty AK, Miller KJ, Ellsworth MK, Glick SD, Gross KW.

Behav Neurosci. 1991 Oct;105(5):755-63.

PMID:
1815622
35.

Side and region dependent changes in dopamine activation with various durations of restraint stress.

Carlson JN, Fitzgerald LW, Keller RW Jr, Glick SD.

Brain Res. 1991 Jun 7;550(2):313-8.

PMID:
1884238
36.

Serotonin metabolism by monoamine oxidase in rat primary astrocyte cultures.

Fitzgerald LW, Kaplinsky L, Kimelberg HK.

J Neurochem. 1990 Dec;55(6):2008-14.

PMID:
1700071
37.

Circling behavior exhibited by a transgenic insertional mutant.

Ratty AK, Fitzgerald LW, Titeler M, Glick SD, Mullins JJ, Gross KW.

Brain Res Mol Brain Res. 1990 Oct;8(4):355-8.

PMID:
1980140
38.

Right-sided population bias in male rats: role of stress.

Fitzgerald LW, Glick SD, Carlson JN.

Physiol Behav. 1990 Sep;48(3):475-7.

PMID:
2267256
39.
40.

Cholinergic maturation and SCH 23390-induced catalepsy in the male rat pup.

Fitzgerald LW, Hannigan JH.

Brain Res Dev Brain Res. 1989 May 1;47(1):147-50.

PMID:
2525433
41.

Absence of differential motoric and thermic responses to clonidine in young rats exposed prenatally to alcohol.

Hannigan JH, Fitzgerald LW, Blanchard BA, Riley EP.

Alcohol. 1988 Nov-Dec;5(6):431-6.

PMID:
3245886

Supplemental Content

Loading ...
Support Center